Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

RAB0537

Sigma-Aldrich

Human FABP2 / Fatty Acid-Binding Protein, Intestinal ELISA Kit

for serum, plasma, cell culture supernatants and urine

Sinónimos:

FABP2 ELISA Kit, Intestinal FABP2 Detection

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable

input

sample type plasma
sample type serum
sample type urine
sample type cell culture supernatant(s)

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 25 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... FABP2(2169)

General description

The antibody pair provided in this kit detects Intestinal, Human Fatty Acid-Binding Protein in serum, plasma, cell culture supernatants, and urine.

Fatty acid-binding protein (FABP2) is an intracellular protein, encoded by the gene mapped to human chromosome 4q28–q31.It is expressed in intestinal enterocytes. FABP2 codes for intestinal FABP (I-FABP).

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

Fatty acid-binding protein (FABP2) plays a vital role in the absorption and intracellular migration of dietary long-chain fatty acids. It also helps in the metabolism of fatty acids. FABP2 acts as a candidate gene for diabetes and insulin resistance. It is also implicated in lipid metabolism and adipogenesis.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Los componentes del kit también están disponibles por separado

Referencia del producto
Descripción
SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

pictograms

Corrosion
GHS05

signalword

Warning

hcodes

H290

Hazard Classifications

Met. Corr. 1

Storage Class

8A - Combustible corrosive hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Lisa Wrba et al.
Shock (Augusta, Ga.), 52(4), e45-e51 (2018-10-06)
Dysfunction of the gut-blood barrier plays an important role in many diseases, such as inflammatory bowel disease, hemorrhagic shock (HS), or burn injury. However, little is known about gut barrier dysfunction after hemodynamically instable polytrauma (PT). Therefore, we aimed to
Marina Saresella et al.
Frontiers in immunology, 11, 1390-1390 (2020-08-01)
Background: Butyric acid (BA) is a short-chain fatty acid (SCFA) with anti-inflammatory properties, which promotes intestinal barrier function. Medium-chain fatty acids (MCFA), including caproic acid (CA), promote TH1 and TH17 differentiation, thus supporting inflammation. Aim: Since most SCFAs are absorbed
Brynjulf Mortensen et al.
Gastroenterology, 157(3), 637-646 (2019-05-17)
Enteropathy and small-intestinal ulcers are common adverse effects of nonsteroidal anti-inflammatory drugs such as acetylsalicylic acid (ASA). Safe, cytoprotective strategies are needed to reduce this risk. Specific bifidobacteria might have cytoprotective activities, but little is known about these effects in
Nicole U Stoffel et al.
The Lancet. Haematology, 4(11), e524-e533 (2017-10-17)
Current guidelines to treat iron deficiency recommend daily provision of ferrous iron divided through the day to increase absorption. However, daily dosing and split dosing might increase serum hepcidin and decrease iron absorption from subsequent doses. Our study aim was
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets.
Furuhashi M and Gokhan S H
Nature Reviews. Drug Discovery, 7(6), 489-489 (2008)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico